HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SPRB
Spruce Biosciences, Inc.
There isn't enough reported data to score SPRB yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SPRB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
SPRB's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SPRB PE Valuation
SPRB has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SPRB Forward outlook
There aren't enough analyst estimates for SPRB to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SPRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$56.56 | +$29.02 |
| Q2 2026 | -$62.63 | +$24.12 |
| Q1 2026 | -$59.45 | +$40.30 |
| Q4 2025 | -$74.51 | +$22.24 |
| Q3 2025 | -$85.58 | -$15.83 |
| Q2 2025 | -$86.75 | -$10.25 |
| Q1 2025 | -$99.75 | -$15.75 |
| Q4 2024 | -$96.75 | -$3.75 |
SPRB is still losing money, but far less than before: $56.56 per share over the past year, against $147.00 at its worst in late 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 100% for SPRB.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SPRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $697K | -76% |
| Q3 2024 | $602K | -80% |
| Q2 2024 | $1.6M | -26% |
| Q1 2024 | $2M | +1.9% |
SPRB's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -3454% | -3067 points |
| Q3 2024 | -1563% | -1118 points |
| Q2 2024 | -623% | +22 points |
| Q1 2024 | -631% | +41 points |
| Q4 2023 | -387% | N/A |
| Q3 2023 | -444% | N/A |
| Q2 2023 | -645% | N/A |
| Q1 2023 | -672% | N/A |
SPRB's operating margin was −3454% last quarter, down 3067 points from the same quarter a year ago, near the bottom of its range since 2023.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SPRB on cash generation, producing positive trailing cash flow while its opponent burns cash.
SPRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$13.8M | -$8.4M |
| Q2 2026 | -$22.3M | -$13.4M |
| Q1 2026 | -$8.7M | +$4M |
| Q4 2025 | -$6.5M | +$14.2M |
| Q2 2025 | -$8.8M | +$2.3M |
| Q1 2025 | -$12.7M | +$2.2M |
| Q4 2024 | -$20.7M | -$9.5M |
| Q1 2024 | -$15M | -$3.2M |
SPRB has burned cash in almost every quarter: −$51M over the past year, against −$48M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SPRB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SPRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +390K shares |
| 1 year | +377% | +2.2M shares |
| 3 years | +422% | +2.3M shares |
| 5 years | +809% | +2.5M shares |
SPRB has 3M diluted shares, up 377% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SPRB Net Leverage
SPRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SPRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 27.3 | Neutral |
SPRB's weekly RSI is 42 (neutral) and its Stochastic is 27 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SPRB PE vs Healthcare Sector
SPRB has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SPRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 4.5% below |
| 20 week MA | $48.4 | 11% below |
| 50 week MA | $58.4 | 27% below |
| 100 week MA | $45.9 | 6.5% below |
| 200 week MA | $86.6 | 50% below |
SPRB is in a downtrend: it's below all five of its weekly moving averages, and 50% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SPRB on returns for 2026, with the stronger performance.
SPRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,275.0 | $1,868.3 | +47% |
| 2021 | $1,868.3 | $279.0 | -85% |
| 2022 | $279.0 | $81.0 | -71% |
| 2023 | $81.0 | $219.8 | +171% |
| 2024 | $219.8 | $32.9 | -85% |
| 2025 | $32.9 | $85.7 | +161% |
| 2026 YTD | $85.7 | $42.9 | -50% |
SPRB's yearly returns have swung widely, from +171% in 2023 to −85% in 2021. It's down 50% so far in 2026.